drugset / Trial / NCT00725582
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8.
Timeline
- Start
- 2008-09
- Primary completion
- 2009-06
- Completion
- 2009-06
Outcome
Missed primary endpoint
paper Treatment with IMA-026 did not attenuate the asthmatic responses on Day 14 or Day 35. PMID 21057005 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMA-026 | Unknown | 2 mg/kg | Subcutaneous |